{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:32Z","timestamp":1792812692146,"version":"4.5.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS120850"],"award-info":[{"award-number":["R01NS120850"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R00AG073453"],"award-info":[{"award-number":["R00AG073453"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017312","name":"Lewy Body Dementia Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To highlight the unique clinical features, risk factors, and management strategies associated with early-onset Parkinson\u2019s disease (EOPD), and contrast these with late-onset Parkinson\u2019s disease (LOPD). We outline how these differences influence diagnostic and therapeutic approaches and identify key knowledge gaps critical to improving clinical care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Compared to LOPD, EOPD (onset age 21-50) has a higher prevalence of monogenic risk factors, focal dystonia, depression, anxiety; slower motor progression; lower rates of cognitive decline; higher risk for delayed diagnosis. Treatment is complicated by earlier and more frequent dyskinesias, motor fluctuations, and unique considerations such as pregnancy and career impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Risk factors, clinical presentation, progression, and management needs of EOPD can differ from LOPD. Despite advances in characterizing and diagnosing EOPD, most research remains focused on LOPD. There is a critical need to tailor research and clinical trials to address the distinct needs of people with EOPD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11910-025-01470-2","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:46:40Z","timestamp":1766040400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early-Onset Parkinson\u2019s Disease: Unique Features and Management Approaches"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-2247","authenticated-orcid":false,"given":"Jordan","family":"Hickman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4383-8893","authenticated-orcid":false,"given":"Andrew","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8749-2487","authenticated-orcid":false,"given":"Michelle","family":"Fullard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4960-4218","authenticated-orcid":false,"given":"Michael","family":"Korsmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-0126","authenticated-orcid":false,"given":"Emily","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7391-7421","authenticated-orcid":false,"given":"Sana","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0009-2756","authenticated-orcid":false,"given":"Alexander J.","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7701-3120","authenticated-orcid":false,"given":"Jeanne S.","family":"Feuerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-4242","authenticated-orcid":false,"given":"Ece","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"1470_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1498756","author":"Y Luo","year":"2025","unstructured":"Luo Y, Qiao L, Li M, Wen X, Zhang W, Li X. Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 2025. https:\/\/doi.org\/10.3389\/fnagi.2024.1498756.","journal-title":"Front Aging Neurosci"},{"key":"1470_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"key":"1470_CR3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mdc3.13523","volume":"9","author":"R Mehanna","year":"2022","unstructured":"Mehanna R, Smilowska K, Fleisher J, Post B, Hatano T, Pimentel Piemonte ME, et al. Age cutoff for early-onset Parkinson\u2019s disease: recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson\u2019s Disease. Mov Disord Clin Pract. 2022;9:869\u201378. https:\/\/doi.org\/10.1002\/mdc3.13523.","journal-title":"Mov Disord Clin Pract"},{"key":"1470_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.parkreldis.2019.06.001","volume":"65","author":"R Mehanna","year":"2019","unstructured":"Mehanna R, Jankovic J. Young-onset parkinson\u2019s disease: its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019;65:39\u201348. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.06.001.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jocn.2024.05.015","volume":"125","author":"F Nabizadeh","year":"2024","unstructured":"Nabizadeh F, Seyedmirzaei H, Rafiei N, Maryam Vafaei S, Shekouh D, Mehrtabar E, et al. Global prevalence and incidence of Young Onset Parkinson\u2019s disease: a systematic review and meta-analysis. J Clin Neurosci. 2024;125:59\u201367. https:\/\/doi.org\/10.1016\/j.jocn.2024.05.015.","journal-title":"J Clin Neurosci"},{"key":"1470_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107778","volume":"134","author":"J Wang","year":"2025","unstructured":"Wang J, Cheng N, Yao Z, Liu J, Kan X, Hui Z, et al. Early-onset Parkinson\u2019s disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: results from the global burden of disease study 2021. Parkinsonism Relat Disord. 2025;134:107778. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107778.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR7","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1007\/s10072-023-06826-5","volume":"44","author":"R Bovenzi","year":"2023","unstructured":"Bovenzi R, Conti M, Degoli GR, Cerroni R, Simonetta C, Liguori C, et al. Shaping the course of early-onset parkinson\u2019s disease: insights from a longitudinal cohort. Neurol Sci. 2023;44:3151\u20139. https:\/\/doi.org\/10.1007\/s10072-023-06826-5.","journal-title":"Neurol Sci"},{"key":"1470_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13020157","volume":"13","author":"L De Carolis","year":"2023","unstructured":"De Carolis L, Galli S, Bianchini E, Rinaldi D, Raju M, Cali\u00f2 B, et al. Age at onset influences progression of motor and non-motor symptoms during the early stage of Parkinson\u2019s disease: a monocentric retrospective study. Brain Sci. 2023;13:157. https:\/\/doi.org\/10.3390\/brainsci13020157.","journal-title":"Brain Sci"},{"key":"1470_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120405","volume":"442","author":"E Angelopoulou","year":"2022","unstructured":"Angelopoulou E, Bozi M, Simitsi A-M, Koros C, Antonelou R, Papagiannakis N, et al. Clinical differences between early-onset and mid-and-late-onset Parkinson\u2019s disease: data analysis of the Hellenic Biobank of Parkinson\u2019s disease. J Neurol Sci. 2022;442:120405. https:\/\/doi.org\/10.1016\/j.jns.2022.120405.","journal-title":"J Neurol Sci"},{"key":"1470_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00415-012-6600-9","volume":"260","author":"V \u0160pica","year":"2013","unstructured":"\u0160pica V, Pekmezovi\u0107 T, Svetel M, Kosti\u0107 VS. Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson\u2019s disease. J Neurol. 2013;260:131\u20137. https:\/\/doi.org\/10.1007\/s00415-012-6600-9.","journal-title":"J Neurol"},{"key":"1470_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1212\/WNL.39.11.1441","volume":"39","author":"SE Starkstein","year":"1989","unstructured":"Starkstein SE, Berthier ML, Bolduc PL, Preziosi TJ, Robinson RG. Depression in patients with early versus late onset of Parkinson\u2019s disease. Neurology. 1989;39:1441\u20131441. https:\/\/doi.org\/10.1212\/WNL.39.11.1441.","journal-title":"Neurology"},{"key":"1470_CR12","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s00415-020-10266-y","volume":"268","author":"M Te Groen","year":"2021","unstructured":"Te Groen M, Bloem BR, Wu SS, Post B. Better quality of life and less caregiver strain in young-onset Parkinson\u2019s disease: a multicentre retrospective cohort study. J Neurol. 2021;268:1102\u20139. https:\/\/doi.org\/10.1007\/s00415-020-10266-y.","journal-title":"J Neurol"},{"key":"1470_CR13","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1007\/s00415-023-11921-w","volume":"270","author":"D Santos-Garc\u00eda","year":"2023","unstructured":"Santos-Garc\u00eda D, de Deus Fonticoba T, Cores Bartolom\u00e9 C, Feal Painceiras MJ, Garc\u00eda D\u00edaz I, \u00cd\u00f1iguez Alvarado MC, et al. Cognitive impairment and dementia in young onset Parkinson\u2019s disease. J Neurol. 2023;270:5793\u2013812. https:\/\/doi.org\/10.1007\/s00415-023-11921-w.","journal-title":"J Neurol"},{"key":"1470_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/mds.27352","volume":"33","author":"M Kasten","year":"2018","unstructured":"Kasten M, Hartmann C, Hampf J, Schaake S, Westenberger A, Vollstedt E, et al. Genotype-phenotype relations for the Parkinson\u2019s disease genes Parkin, PINK1, DJ1: MDSGene systematic review. Mov Disord. 2018;33:730\u201341. https:\/\/doi.org\/10.1002\/mds.27352.","journal-title":"Mov Disord"},{"key":"1470_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","volume":"68","author":"G Giovannoni","year":"2000","unstructured":"Giovannoni G. Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68:423\u20138. https:\/\/doi.org\/10.1136\/jnnp.68.4.423.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1470_CR16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mds.22875","volume":"25","author":"YJ Zhao","year":"2010","unstructured":"Zhao YJ, Wee HL, Chan Y, Seah SH, Au WL, Lau PN, et al. Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord. 2010;25:710\u20136. https:\/\/doi.org\/10.1002\/mds.22875.","journal-title":"Mov Disord"},{"key":"1470_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mds.27882","volume":"35","author":"H Kim","year":"2020","unstructured":"Kim H, Mason S, Foltynie T, Winder-Rhodes S, Barker RA, Williams\u2010Gray CH. Motor complications in Parkinson\u2019s disease: 13\u2010year follow\u2010up of the CamPaIGN cohort. Mov Disord. 2020;35:185\u201390. https:\/\/doi.org\/10.1002\/mds.27882.","journal-title":"Mov Disord"},{"key":"1470_CR18","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/mds.25898","volume":"29","author":"AD Macleod","year":"2014","unstructured":"Macleod AD, Taylor KSM, Counsell CE. Mortality in parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1615\u201322. https:\/\/doi.org\/10.1002\/mds.25898.","journal-title":"Mov Disord"},{"key":"1470_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3233\/JPD-230049","volume":"13","author":"E Camerucci","year":"2023","unstructured":"Camerucci E, Mullan AF, Turcano P, Bower J, Piat C, Ahlskog JE, et al. 40-year incidence of early-onset Parkinson\u2019s disease in Southeast Minnesota. J Parkinsons Dis. 2023;13:893\u20138. https:\/\/doi.org\/10.3233\/JPD-230049.","journal-title":"J Parkinsons Dis"},{"key":"1470_CR20","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/mds.10527","volume":"18","author":"A Schrag","year":"2003","unstructured":"Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Young- versus older\u2010onset parkinson\u2019s disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18:1250\u20136. https:\/\/doi.org\/10.1002\/mds.10527.","journal-title":"Mov Disord"},{"key":"1470_CR21","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/mds.23763","volume":"26","author":"MDW Knipe","year":"2011","unstructured":"Knipe MDW, Wickremaratchi MM, Wyatt-Haines E, Morris HR, Ben\u2010Shlomo Y. Quality of life in young\u2010 compared with late\u2010onset parkinson\u2019s disease. Mov Disord. 2011;26:2011\u20138. https:\/\/doi.org\/10.1002\/mds.23763.","journal-title":"Mov Disord"},{"key":"1470_CR22","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1080\/09638288.2024.2444481","volume":"47","author":"E Cullen","year":"2025","unstructured":"Cullen E, Eccles FJR, Byrne G, Dow M, Dwyer B, O\u2019Riordan S, et al. \u201cA young person in an old person\u2019s body\u201d: a reflexive thematic analysis of the experience of living with young onset Parkinson\u2019s disease. Disabil Rehabil. 2025;47:4159\u201367. https:\/\/doi.org\/10.1080\/09638288.2024.2444481.","journal-title":"Disabil Rehabil"},{"key":"1470_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105395","volume":"110","author":"B McDaniels","year":"2023","unstructured":"McDaniels B, Subramanian I, Kurian S, Chitnis S. Early-onset Parkinson\u2019s disease: an assessment of unmet psychosocial needs. Parkinsonism Relat Disord. 2023;110:105395. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105395.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR24","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1212\/WNL.55.10.1572","volume":"55","author":"K Kompoliti","year":"2000","unstructured":"Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with parkinson\u2019s disease. Neurology. 2000;55:1572\u20135. https:\/\/doi.org\/10.1212\/WNL.55.10.1572.","journal-title":"Neurology"},{"key":"1470_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/mds.870010112","volume":"1","author":"NP Quinn","year":"1986","unstructured":"Quinn NP, Marsden CD. Menstrual-related fluctuations in parkinson\u2019s disease. Mov Disord. 1986;1:85\u20137. https:\/\/doi.org\/10.1002\/mds.870010112.","journal-title":"Mov Disord"},{"key":"1470_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.disamonth.2007.02.002","volume":"53","author":"SM Rubin","year":"2007","unstructured":"Rubin SM. Parkinson\u2019s disease in women. Dis Mon. 2007;53:206\u201313. https:\/\/doi.org\/10.1016\/j.disamonth.2007.02.002.","journal-title":"Dis Mon"},{"key":"1470_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/mdc3.12925","volume":"7","author":"C Young","year":"2020","unstructured":"Young C, Phillips R, Ebenezer L, Zutt R, Peall KJ. Management of parkinson\u2019s disease during pregnancy: literature review and multidisciplinary input. Mov Disord Clin Pract. 2020;7:419\u201330. https:\/\/doi.org\/10.1002\/mdc3.12925.","journal-title":"Mov Disord Clin Pract"},{"key":"1470_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.parkreldis.2017.05.007","volume":"40","author":"M Seier","year":"2017","unstructured":"Seier M, Hiller A. Parkinson\u2019s disease and pregnancy: an updated review. Parkinsonism Relat Disord. 2017;40:11\u20137. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.05.007.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR29","doi-asserted-by":"publisher","unstructured":"Olszewska DA, Lynch T. Will crystal parkin help in Understanding the future of parkinson\u2019s disease? Front Neurol. 2015;6. https:\/\/doi.org\/10.3389\/fneur.2015.00035.","DOI":"10.3389\/fneur.2015.00035"},{"key":"1470_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104782","volume":"137","author":"S Bandres-Ciga","year":"2020","unstructured":"Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson\u2019s disease: an introspection of its journey towards precision medicine. Neurobiol Dis. 2020;137:104782. https:\/\/doi.org\/10.1016\/j.nbd.2020.104782.","journal-title":"Neurobiol Dis"},{"key":"1470_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/cells13040296","volume":"13","author":"LD Skou","year":"2024","unstructured":"Skou LD, Johansen SK, Okarmus J, Meyer M. Pathogenesis of DJ-1\/PARK7-mediated parkinson\u2019s disease. Cells. 2024;13:296. https:\/\/doi.org\/10.3390\/cells13040296.","journal-title":"Cells"},{"key":"1470_CR32","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.parkreldis.2015.09.007","volume":"22","author":"T Konno","year":"2016","unstructured":"Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK. Autosomal dominant parkinson\u2019s disease caused by SNCA duplications. Parkinsonism Relat Disord. 2016;22:S1\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.007.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR33","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/brain\/awae142","volume":"147","author":"L Cook","year":"2024","unstructured":"Cook L, Verbrugge J, Schwantes-An T-H, Schulze J, Foroud T, Hall A, et al. Parkinson\u2019s disease variant detection and disclosure: PD GENEration, a North American study. Brain. 2024;147:2668\u201379. https:\/\/doi.org\/10.1093\/brain\/awae142.","journal-title":"Brain"},{"key":"1470_CR34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/mds.28353","volume":"36","author":"EI Sarihan","year":"2021","unstructured":"Sarihan EI, P\u00e9rez-Palma E, Niestroj L, Loesch D, Inca\u2010Martinez M, Horimoto ARVR, et al. Genome\u2010wide analysis of copy number variation in Latin American Parkinson\u2019s disease patients. Mov Disord. 2021;36:434\u201341. https:\/\/doi.org\/10.1002\/mds.28353.","journal-title":"Mov Disord"},{"key":"1470_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/mds.29676","volume":"39","author":"SV Andrews","year":"2024","unstructured":"Andrews SV, Kukkle PL, Menon R, Geetha TS, Goyal V, Kandadai RM, et al. The genetic drivers of juvenile, young, and early-onset Parkinson\u2019s disease in India. Mov Disord. 2024;39:339\u201349. https:\/\/doi.org\/10.1002\/mds.29676.","journal-title":"Mov Disord"},{"key":"1470_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.parkreldis.2016.04.024","volume":"32","author":"MM Abbas","year":"2016","unstructured":"Abbas MM, Govindappa ST, Sudhaman S, Thelma BK, Juyal RC, Behari M, et al. Early onset Parkinson\u2019s disease due to DJ1 mutations: an Indian study. Parkinsonism Relat Disord. 2016;32:20\u20134. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.024.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR37","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1111\/ene.15509","volume":"29","author":"Y Chen","year":"2022","unstructured":"Chen Y, Yu S, Zhang G, Hou Y, Gu X, Ou R, et al. The mutation spectrum of Parkinson-disease\u2010related genes in early\u2010onset Parkinson\u2019s disease in ethnic Chinese. Eur J Neurol. 2022;29:3218\u201328. https:\/\/doi.org\/10.1111\/ene.15509.","journal-title":"Eur J Neurol"},{"key":"1470_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1474-4422(21)00100-9","volume":"20","author":"M Rizig","year":"2021","unstructured":"Rizig M, Okubadejo N, Salama M, Thomas O, Akpalu A, Gouider R. The international Parkinson disease genomics consortium Africa. Lancet Neurol. 2021;20:335. https:\/\/doi.org\/10.1016\/S1474-4422(21)00100-9.","journal-title":"Lancet Neurol"},{"key":"1470_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","volume":"22","author":"M Rizig","year":"2023","unstructured":"Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, et al. Identification of genetic risk loci and causal insights associated with Parkinson\u2019s disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023;22:1015\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(23)00283-1.","journal-title":"Lancet Neurol"},{"key":"1470_CR40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/ana.24335","volume":"77","author":"V Escott-Price","year":"2015","unstructured":"Escott-Price V, Nalls MA, Morris HR, Lubbe S, Brice A, Gasser T, et al. Polygenic risk of Parkinson disease is correlated with disease age at onset. Ann Neurol. 2015;77:582\u201391. https:\/\/doi.org\/10.1002\/ana.24335.","journal-title":"Ann Neurol"},{"key":"1470_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12883-017-0978-z","volume":"17","author":"L Ibanez","year":"2017","unstructured":"Ibanez L, Dube U, Saef B, Budde J, Black K, Medvedeva A, et al. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurol. 2017;17:198. https:\/\/doi.org\/10.1186\/s12883-017-0978-z.","journal-title":"BMC Neurol"},{"key":"1470_CR42","doi-asserted-by":"publisher","first-page":"14670","DOI":"10.1038\/s41598-024-65640-x","volume":"14","author":"C Gabbert","year":"2024","unstructured":"Gabbert C, Bl\u00f6baum L, L\u00fcth T, K\u00f6nig IR, Caliebe A, Sendel S, et al. The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson\u2019s disease. Sci Rep. 2024;14:14670. https:\/\/doi.org\/10.1038\/s41598-024-65640-x.","journal-title":"Sci Rep"},{"key":"1470_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/genes12121859","author":"S Koch","year":"2021","unstructured":"Koch S, Laabs B-H, Kasten M, Vollstedt E-J, Becktepe J, Br\u00fcggemann N, et al. Validity and prognostic value of a polygenic risk score for Parkinson\u2019s disease. Genes. 2021. https:\/\/doi.org\/10.3390\/genes12121859.","journal-title":"Genes"},{"key":"1470_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/brain\/awu323","volume":"138","author":"F Yang","year":"2015","unstructured":"Yang F, Trolle Lagerros Y, Bellocco R, Adami H-O, Fang F, Pedersen NL, et al. Physical activity and risk of parkinson\u2019s disease in the Swedish National March cohort. Brain. 2015;138:269\u201375. https:\/\/doi.org\/10.1093\/brain\/awu323.","journal-title":"Brain"},{"key":"1470_CR45","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0303-8467(02)00027-6","volume":"104","author":"CH Tsai","year":"2002","unstructured":"Tsai CH, Lo SK, See LC, Chen HZ, Chen RS, Weng YH, et al. Environmental risk factors of young onset Parkinson\u2019s disease: a case-control study. Clin Neurol Neurosurg. 2002;104:328\u201333. https:\/\/doi.org\/10.1016\/S0303-8467(02)00027-6.","journal-title":"Clin Neurol Neurosurg"},{"key":"1470_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010523","author":"S Molsberry","year":"2020","unstructured":"Molsberry S, Bjornevik K, Hughes KC, Healy B, Schwarzschild M, Ascherio A. Diet pattern and prodromal features of Parkinson disease. Neurology. 2020. https:\/\/doi.org\/10.1212\/WNL.0000000000010523.","journal-title":"Neurology"},{"key":"1470_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6405278","author":"LK Mischley","year":"2017","unstructured":"Mischley LK, Lau RC, Bennett RD. Role of diet and nutritional supplements in Parkinson\u2019s Disease progression. Oxid Med Cell Longev. 2017. https:\/\/doi.org\/10.1155\/2017\/6405278.","journal-title":"Oxid Med Cell Longev"},{"key":"1470_CR48","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/archneur.64.7.990","volume":"64","author":"B Ritz","year":"2007","unstructured":"Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64:990. https:\/\/doi.org\/10.1001\/archneur.64.7.990.","journal-title":"Arch Neurol"},{"key":"1470_CR49","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","volume":"283","author":"GW Ross","year":"2000","unstructured":"Ross GW. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283:2674. https:\/\/doi.org\/10.1001\/jama.283.20.2674.","journal-title":"JAMA"},{"key":"1470_CR50","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/mds.30067","volume":"40","author":"K Atterling Brolin","year":"2025","unstructured":"Atterling Brolin K, Schaeffer E, Kuri A, Rumrich IK, Schumacher Schuh AF, Darweesh SKL, et al. Environmental risk factors for Parkinson\u2019s disease: a critical review and policy implications. Mov Disord. 2025;40:204\u201321. https:\/\/doi.org\/10.1002\/mds.30067.","journal-title":"Mov Disord"},{"key":"1470_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yrtph.2018.05.005","volume":"96","author":"D Yan","year":"2018","unstructured":"Yan D, Zhang Y, Liu L, Shi N, Yan H. Pesticide exposure and risk of Parkinson\u2019s disease: dose-response meta-analysis of observational studies. Regul Toxicol Pharmacol. 2018;96:57\u201363. https:\/\/doi.org\/10.1016\/j.yrtph.2018.05.005.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1470_CR52","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1212\/WNL.35.7.949","volume":"35","author":"PA Ballard","year":"1985","unstructured":"Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methy 1\u20134\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP). Neurology. 1985;35:949\u2013949. https:\/\/doi.org\/10.1212\/WNL.35.7.949.","journal-title":"Neurology"},{"key":"1470_CR53","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jamaneurol.2023.1168","volume":"80","author":"SM Goldman","year":"2023","unstructured":"Goldman SM, Weaver FM, Stroupe KT, Cao L, Gonzalez B, Colletta K, et al. Risk of Parkinson disease among service members at marine corps base camp lejeune. JAMA Neurol. 2023;80:673. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1168.","journal-title":"JAMA Neurol"},{"key":"1470_CR54","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1046\/j.1468-1331.1999.650609.x","volume":"6","author":"D Guehl","year":"1999","unstructured":"Guehl D, Bezard E, Dovero S, Boraud T, Bioulac B, Gross C. Trichloroethylene and parkinsonism: a human and experimental observation. Eur J Neurol. 1999;6:609\u201311. https:\/\/doi.org\/10.1046\/j.1468-1331.1999.650609.x.","journal-title":"Eur J Neurol"},{"key":"1470_CR55","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2020-323646","volume":"91","author":"BM Jacobs","year":"2020","unstructured":"Jacobs BM, Belete D, Bestwick J, Blauwendraat C, Bandres-Ciga S, Heilbron K, et al. Parkinson\u2019s disease determinants, prediction and gene\u2013environment interactions in the UK biobank. J Neurol Neurosurg Psychiatry. 2020;91:1046\u201354. https:\/\/doi.org\/10.1136\/jnnp-2020-323646.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1470_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jns.2012.08.029","volume":"323","author":"AQ Rana","year":"2012","unstructured":"Rana AQ, Siddiqui I, Yousuf MS. Challenges in diagnosis of young onset Parkinson\u2019s disease. J Neurol Sci. 2012;323:113\u20136. https:\/\/doi.org\/10.1016\/j.jns.2012.08.029.","journal-title":"J Neurol Sci"},{"key":"1470_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-212815","volume":"12","author":"GM Riboldi","year":"2022","unstructured":"Riboldi GM, Frattini E, Monfrini E, Frucht SJ, Di Fonzo A. A practical approach to early-onset Parkinsonism. J Parkinsons Dis. 2022;12:1\u201326. https:\/\/doi.org\/10.3233\/JPD-212815.","journal-title":"J Parkinsons Dis"},{"key":"1470_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107852","volume":"135","author":"R Mehanna","year":"2025","unstructured":"Mehanna R, Marras C, Fleisher J, Post B, Kumar KR, Noyce A, et al. Diagnostic work up when suspecting early onset Parkinson disease (EOPD). Recommendations from the MDS EOPD study group. Parkinsonism Relat Disord. 2025;135:107852. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107852.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR59","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/JPRLS.S99197","volume":"6","author":"P Blanchet","year":"2016","unstructured":"Blanchet P, Kivenko V. Drug-induced parkinsonism: diagnosis and management. J Parkinsonism Restless Legs Syndrome. 2016;6:83\u201391. https:\/\/doi.org\/10.2147\/JPRLS.S99197.","journal-title":"J Parkinsonism Restless Legs Syndrome"},{"key":"1470_CR60","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/TCRM.S360268","volume":"18","author":"M Feldman","year":"2022","unstructured":"Feldman M, Marmol S, Margolesky J. Updated perspectives on the management of drug-induced parkinsonism (DIP): insights from the clinic. Ther Clin Risk Manag. 2022;18:1129\u201342. https:\/\/doi.org\/10.2147\/TCRM.S360268.","journal-title":"Ther Clin Risk Manag"},{"key":"1470_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00615-9","volume":"9","author":"L Shan","year":"2023","unstructured":"Shan L, Heusinkveld HJ, Paul KC, Hughes S, Darweesh SKL, Bloem BR, et al. Towards improved screening of toxins for Parkinson\u2019s risk. NPJ Parkinsons Dis. 2023;9:169. https:\/\/doi.org\/10.1038\/s41531-023-00615-9.","journal-title":"NPJ Parkinsons Dis"},{"key":"1470_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120014","volume":"433","author":"F Xing","year":"2022","unstructured":"Xing F, Marsili L, Truong DD. Parkinsonism in viral, paraneoplastic, and autoimmune diseases. J Neurol Sci. 2022;433:120014. https:\/\/doi.org\/10.1016\/j.jns.2021.120014.","journal-title":"J Neurol Sci"},{"key":"1470_CR63","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/B978-0-444-63625-6.00005-7","volume":"142","author":"IF Scheiber","year":"2017","unstructured":"Scheiber IF, Br\u016fha R, Du\u0161ek P. Pathogenesis of Wilson disease. Handb Clin Neurol. 2017;142:43\u201355. https:\/\/doi.org\/10.1016\/B978-0-444-63625-6.00005-7.","journal-title":"Handb Clin Neurol"},{"key":"1470_CR64","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/B978-0-444-52014-2.00039-2","volume":"100","author":"M Segawa","year":"2011","unstructured":"Segawa M. Dopa-responsive dystonia. Handb Clin Neurol. 2011;100:539\u201357. https:\/\/doi.org\/10.1016\/B978-0-444-52014-2.00039-2.","journal-title":"Handb Clin Neurol"},{"key":"1470_CR65","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","volume":"22","author":"TB Stoker","year":"2022","unstructured":"Stoker TB, Mason SL, Greenland JC, Holden ST, Santini H, Barker RA. Huntington\u2019s disease: diagnosis and management. Pract Neurol. 2022;22:32\u201341. https:\/\/doi.org\/10.1136\/practneurol-2021-003074.","journal-title":"Pract Neurol"},{"key":"1470_CR66","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","volume":"266","author":"R Sullivan","year":"2019","unstructured":"Sullivan R, Yau WY, O\u2019Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266:533\u201344. https:\/\/doi.org\/10.1007\/s00415-018-9076-4.","journal-title":"J Neurol"},{"key":"1470_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.14034","volume":"8","author":"P Hogarth","year":"2015","unstructured":"Hogarth P. Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord. 2015;8:1\u201313. https:\/\/doi.org\/10.14802\/jmd.14034.","journal-title":"J Mov Disord"},{"key":"1470_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11910-018-0819-5","volume":"18","author":"MJ Armstrong","year":"2018","unstructured":"Armstrong MJ. Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep. 2018;18:12. https:\/\/doi.org\/10.1007\/s11910-018-0819-5.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1470_CR69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.prdoa.2019.08.005","volume":"1","author":"VC Constantinides","year":"2019","unstructured":"Constantinides VC, Paraskevas GP, Paraskevas PG, Stefanis L, Kapaki E. Corticobasal degeneration and corticobasal syndrome: a review. Clin Park Relat Disord. 2019;1:66\u201371. https:\/\/doi.org\/10.1016\/j.prdoa.2019.08.005.","journal-title":"Clin Park Relat Disord"},{"key":"1470_CR70","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/pn-2020-002797","volume":"23","author":"YY Goh","year":"2023","unstructured":"Goh YY, Saunders E, Pavey S, Rushton E, Quinn N, Houlden H, et al. Multiple system atrophy. Pract Neurol. 2023;23:208\u201321. https:\/\/doi.org\/10.1136\/pn-2020-002797.","journal-title":"Pract Neurol"},{"key":"1470_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2023.100074","volume":"9","author":"KY Yamashita","year":"2023","unstructured":"Yamashita KY, Bhoopatiraju S, Silverglate BD, Grossberg GT. Biomarkers in Parkinson\u2019s disease: a state of the art review. Biomark Neuropsychiatry. 2023;9:100074. https:\/\/doi.org\/10.1016\/j.bionps.2023.100074.","journal-title":"Biomark Neuropsychiatry"},{"key":"1470_CR72","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s13311-023-01379-z","volume":"20","author":"DG Coughlin","year":"2023","unstructured":"Coughlin DG, Irwin DJ. Fluid and biopsy based biomarkers in parkinson\u2019s disease. Neurotherapeutics. 2023;20:932\u201354. https:\/\/doi.org\/10.1007\/s13311-023-01379-z.","journal-title":"Neurotherapeutics"},{"key":"1470_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/S40478-021-01282-8","author":"MJ Russo","year":"2021","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM, et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commun. 2021. https:\/\/doi.org\/10.1186\/S40478-021-01282-8.","journal-title":"Acta Neuropathol Commun"},{"key":"1470_CR74","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant D-E, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22:407\u201317. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6.","journal-title":"Lancet Neurol"},{"key":"1470_CR75","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-021-01276-6","volume":"9","author":"K Brockmann","year":"2021","unstructured":"Brockmann K, Quadalti C, Lerche S, Rossi M, Wurster I, Baiardi S, et al. Association between CSF alpha-synuclein seeding activity and genetic status in parkinson\u2019s disease and dementia with lewy bodies. Acta Neuropathol Commun. 2021;9:175. https:\/\/doi.org\/10.1186\/s40478-021-01276-6.","journal-title":"Acta Neuropathol Commun"},{"key":"1470_CR76","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2020.02.012","volume":"90","author":"T Schirinzi","year":"2020","unstructured":"Schirinzi T, Di Lazzaro G, Sancesario GM, Summa S, Petrucci S, Colona VL, et al. Young-onset and late-onset Parkinson\u2019s disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiol Aging. 2020;90:119\u201324. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.02.012.","journal-title":"Neurobiol Aging"},{"key":"1470_CR77","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, et al. Blood-based NfL. Neurology. 2017;88:930\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000003680.","journal-title":"Neurology"},{"key":"1470_CR78","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1038\/s41467-024-49949-9","volume":"15","author":"A Zarkali","year":"2024","unstructured":"Zarkali A, Thomas GEC, Zetterberg H, Weil RS. Neuroimaging and fluid biomarkers in parkinson\u2019s disease in an era of targeted interventions. Nat Commun. 2024;15:5661. https:\/\/doi.org\/10.1038\/s41467-024-49949-9.","journal-title":"Nat Commun"},{"key":"1470_CR79","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.parkreldis.2020.06.019","volume":"77","author":"C Koros","year":"2020","unstructured":"Koros C, Simitsi A-M, Prentakis A, Papagiannakis N, Bougea A, Pachi I, et al. <article-title update=\"added\">DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson\u2019s disease: longitudinal data from the PPMI study. Parkinsonism Relat Disord. 2020;77:36\u201342. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.06.019.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR80","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54337","author":"S Das","year":"2024","unstructured":"Das S, Ramteke H. A comprehensive review of the role of biomarkers in early diagnosis of Parkinson\u2019s disease. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.54337.","journal-title":"Cureus"},{"key":"1470_CR81","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00702-024-02797-9","volume":"131","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Lang AE. The why and how of the synnerge criteria of Parkinson\u00b4s disease. J Neural Transm. 2024;131:1149\u201354. https:\/\/doi.org\/10.1007\/s00702-024-02797-9.","journal-title":"J Neural Transm"},{"key":"1470_CR82","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23:191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0.","journal-title":"Lancet Neurol"},{"key":"1470_CR83","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23:178\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"key":"1470_CR84","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.3233\/JPD-202135","volume":"10","author":"B Post","year":"2020","unstructured":"Post B, van den Heuvel L, van Prooije T, van Ruissen X, van de Warrenburg B, Nonnekes J. Young Onset Parkinson\u2019s Disease: A Modern and Tailored Approach. J Parkinsons Dis. 2020;10:S29-36. https:\/\/doi.org\/10.3233\/JPD-202135.","journal-title":"J Parkinsons Dis"},{"key":"1470_CR85","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1212\/WNL.41.2_Part_1.202","volume":"41","author":"V Kostic","year":"1991","unstructured":"Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young\u2010onset Parkinson\u2019s disease. Neurology. 1991;41:202\u2013202. https:\/\/doi.org\/10.1212\/WNL.41.2_Part_1.202.","journal-title":"Neurology"},{"key":"1470_CR86","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/mds.23469","volume":"26","author":"MM Wickremaratchi","year":"2011","unstructured":"Wickremaratchi MM, Knipe MDW, Sastry BSD, Morgan E, Jones A, Salmon R, et al. The motor phenotype of Parkinson\u2019s disease in relation to age at onset. Mov Disord. 2011;26:457\u201363. https:\/\/doi.org\/10.1002\/mds.23469.","journal-title":"Mov Disord"},{"key":"1470_CR87","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.25364","volume":"84","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, et al. Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol. 2018;84:797\u2013811. https:\/\/doi.org\/10.1002\/ana.25364.","journal-title":"Ann Neurol"},{"key":"1470_CR88","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.14336\/AD.2020.1225","volume":"12","author":"D Nemade","year":"2021","unstructured":"Nemade D, Subramanian T, Shivkumar V. An update on medical and surgical treatments of parkinson\u2019s disease. Aging Dis. 2021;12:1021. https:\/\/doi.org\/10.14336\/AD.2020.1225.","journal-title":"Aging Dis"},{"key":"1470_CR89","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, et al. Randomized delayed-start trial of levodopa in parkinson\u2019s disease. N Engl J Med. 2019;380:315\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1809983.","journal-title":"N Engl J Med"},{"key":"1470_CR90","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"PD MED Collaborative Group","year":"2014","unstructured":"PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196\u2013205. https:\/\/doi.org\/10.1016\/S0140-6736(14)60683-8.","journal-title":"Lancet"},{"key":"1470_CR91","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of parkinson\u2019s disease. N Engl J Med. 2004;351:2498\u2013508. https:\/\/doi.org\/10.1056\/NEJMoa033447.","journal-title":"N Engl J Med"},{"key":"1470_CR92","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S1353-8020(09)70835-1","volume":"15","author":"U Bonuccelli","year":"2009","unstructured":"Bonuccelli U, Del Dotto P, Rascol O. Role of dopamine receptor agonists in the treatment of early Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009;15:S44-53. https:\/\/doi.org\/10.1016\/S1353-8020(09)70835-1.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR93","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s00415-019-09360-7","volume":"266","author":"S Kasamo","year":"2019","unstructured":"Kasamo S, Takeuchi M, Ikuno M, Kawasaki Y, Tanaka S, Takahashi R, et al. Real-world pharmacological treatment patterns of patients with young-onset parkinson\u2019s disease in japan: a medical claims database analysis. J Neurol. 2019;266:1944\u201352. https:\/\/doi.org\/10.1007\/s00415-019-09360-7.","journal-title":"J Neurol"},{"key":"1470_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.858139","author":"X Liu","year":"2022","unstructured":"Liu X, Wang X, Shen H, Pang W, Zhong M, Ma C. Real-world prescription patterns for patients with young-onset Parkinson\u2019s disease in China: a trend analysis from 2014 to 2019. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.858139.","journal-title":"Front Pharmacol"},{"key":"1470_CR95","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/00002512-200522090-00002","volume":"22","author":"A Lees","year":"2005","unstructured":"Lees A. Alternatives to levodopa in the initial treatment of early Parkinson\u2019s disease. Drugs Aging. 2005;22:731\u201340. https:\/\/doi.org\/10.2165\/00002512-200522090-00002.","journal-title":"Drugs Aging"},{"key":"1470_CR96","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/00207454.2021.1929217","volume":"133","author":"M Feldman","year":"2023","unstructured":"Feldman M, Margolesky J. Opicapone for the treatment of parkinson\u2019s disease: a review. Int J Neurosci. 2023;133:532\u201343. https:\/\/doi.org\/10.1080\/00207454.2021.1929217.","journal-title":"Int J Neurosci"},{"key":"1470_CR97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40035-020-00187-1","volume":"9","author":"H Reichmann","year":"2020","unstructured":"Reichmann H, Lees A, Rocha J-F, Magalh\u00e3es D, Soares-da-Silva P. Effectiveness and safety of opicapone in parkinson\u2019s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020;9:9. https:\/\/doi.org\/10.1186\/s40035-020-00187-1.","journal-title":"Transl Neurodegener"},{"key":"1470_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106088","volume":"122","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Ostrem JL, Formella AE, Tanner CM. Extended-release amantadine for OFF-related dystonia in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2024;122:106088. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106088.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR99","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","volume":"20","author":"O Rascol","year":"2021","unstructured":"Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of parkinson\u2019s disease and other movement disorders. Lancet Neurol. 2021;20:1048\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(21)00249-0.","journal-title":"Lancet Neurol"},{"key":"1470_CR100","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JPD-225060","volume":"13","author":"W Pirker","year":"2023","unstructured":"Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological treatment of tremor in parkinson\u2019s disease revisited. J Parkinsons Dis. 2023;13:127\u201344. https:\/\/doi.org\/10.3233\/JPD-225060.","journal-title":"J Parkinsons Dis"},{"key":"1470_CR101","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/WCO.0000000000001277","volume":"37","author":"MN Dean","year":"2024","unstructured":"Dean MN, Standaert DG. Levodopa infusion therapies for Parkinson disease. Curr Opin Neurol. 2024;37:409\u201313. https:\/\/doi.org\/10.1097\/WCO.0000000000001277.","journal-title":"Curr Opin Neurol"},{"key":"1470_CR102","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(18)30239-4.","journal-title":"Lancet Neurol"},{"key":"1470_CR103","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10072-023-07173-1","volume":"45","author":"R Balestrino","year":"2024","unstructured":"Balestrino R, Martone T, Toffoli M, Montanaro E, Fabbri M, Artusi CA, et al. Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations. Neurol Sci. 2024;45:1489\u201397. https:\/\/doi.org\/10.1007\/s10072-023-07173-1.","journal-title":"Neurol Sci"},{"key":"1470_CR104","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.parkreldis.2012.09.014","volume":"19","author":"AW Willis","year":"2013","unstructured":"Willis AW, Schootman M, Kung N, Racette BA. Epidemiology and neuropsychiatric manifestations of young onset Parkinson\u2019s disease in the United States. Parkinsonism Relat Disord. 2013;19:202\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.09.014.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR105","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/ane.13256","volume":"142","author":"KJ Biddiscombe","year":"2020","unstructured":"Biddiscombe KJ, Ong B, Kalinowski P, Pike KE. Physical activity and cognition in young-onset Parkinson\u2019s disease. Acta Neurol Scand. 2020;142:151\u201360. https:\/\/doi.org\/10.1111\/ane.13256.","journal-title":"Acta Neurol Scand"},{"key":"1470_CR106","doi-asserted-by":"publisher","unstructured":"Ernst M, Folkerts A-K, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, et al. Physical exercise for people with parkinson\u2019s disease: a systematic review and network meta-analysis. Cochrane Database Syst Reviews. 2023;2023. https:\/\/doi.org\/10.1002\/14651858.CD013856.pub2.","DOI":"10.1002\/14651858.CD013856.pub2"},{"key":"1470_CR107","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ana.26291","volume":"91","author":"ME Johansson","year":"2022","unstructured":"Johansson ME, Cameron IGM, Van der Kolk NM, de Vries NM, Klimars E, Toni I, et al. Aerobic exercise alters brain function and structure in Parkinson\u2019s disease: a randomized controlled trial. Ann Neurol. 2022;91:203\u201316. https:\/\/doi.org\/10.1002\/ana.26291.","journal-title":"Ann Neurol"},{"key":"1470_CR108","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease; a randomized controlled trial. JAMA. 2009;301:63. https:\/\/doi.org\/10.1001\/jama.2008.929.","journal-title":"JAMA"},{"key":"1470_CR109","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Sch\u00e4fer H, B\u00f6tzel K, et al. A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med. 2006;355:896\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa060281.","journal-title":"N Engl J Med"},{"key":"1470_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1177889","author":"J Hong","year":"2024","unstructured":"Hong J, Xie H, Chen Y, Liu D, Wang T, Xiong K, et al. Effects of STN-DBS on cognition and mood in young-onset Parkinson\u2019s disease: a two-year follow-up. Front Aging Neurosci. 2024. https:\/\/doi.org\/10.3389\/fnagi.2023.1177889.","journal-title":"Front Aging Neurosci"},{"key":"1470_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1041449","author":"P Krause","year":"2022","unstructured":"Krause P, Reimer J, Kaplan J, Borngr\u00e4ber F, Schneider G-H, Faust K, et al. Deep brain stimulation in early onset Parkinson\u2019s disease. Front Neurol. 2022. https:\/\/doi.org\/10.3389\/fneur.2022.1041449.","journal-title":"Front Neurol"},{"key":"1470_CR112","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jocn.2019.08.065","volume":"70","author":"A Vats","year":"2019","unstructured":"Vats A, Amit A, Doshi P. A comparative study of bilateral subthalamic nucleus DBS in Parkinson\u2019s disease in young versus old: a single institutional study. J Clin Neurosci. 2019;70:85\u201391. https:\/\/doi.org\/10.1016\/j.jocn.2019.08.065.","journal-title":"J Clin Neurosci"},{"key":"1470_CR113","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WMM Schuepbach","year":"2013","unstructured":"Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med. 2013;368:610\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1205158.","journal-title":"N Engl J Med"},{"key":"1470_CR114","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","volume":"17","author":"E Lhomm\u00e9e","year":"2018","unstructured":"Lhomm\u00e9e E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson\u2019s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol. 2018;17:223\u201331. https:\/\/doi.org\/10.1016\/S1474-4422(18)30035-8.","journal-title":"Lancet Neurol"},{"key":"1470_CR115","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.parkreldis.2014.02.013","volume":"20","author":"R Mehanna","year":"2014","unstructured":"Mehanna R, Moore S, Hou JG, Sarwar AI, Lai EC. Comparing clinical features of young onset, middle onset and late onset parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20:530\u20134. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.02.013.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR116","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/mds.24999","volume":"27","author":"M Kasten","year":"2012","unstructured":"Kasten M, Kertelge L, Tadic V, Br\u00fcggemann N, Schmidt A, van der Vegt J, et al. Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson\u2019s disease. Mov Disord. 2012;27:754\u20139. https:\/\/doi.org\/10.1002\/mds.24999.","journal-title":"Mov Disord"},{"key":"1470_CR117","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s00415-020-10333-4","volume":"268","author":"R Ou","year":"2021","unstructured":"Ou R, Wei Q, Hou Y, Zhang L, Liu K, Kong X, et al. Suicidal ideation in early-onset parkinson\u2019s disease. J Neurol. 2021;268:1876\u201384. https:\/\/doi.org\/10.1007\/s00415-020-10333-4.","journal-title":"J Neurol"},{"key":"1470_CR118","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.parkreldis.2014.03.019","volume":"20","author":"D Charles","year":"2014","unstructured":"Charles D, Konrad PE, Neimat JS, Molinari AL, Tramontana MG, Finder SG, et al. Subthalamic nucleus deep brain stimulation in early stage Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20:731\u20137. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.03.019.","journal-title":"Parkinsonism Relat Disord"},{"key":"1470_CR119","doi-asserted-by":"publisher","unstructured":"Scelzo E, Mehrkens JH, B\u00f6tzel K, Krack P, Mendes A, Chabard\u00e8s S, et al. Deep brain stimulation during pregnancy and delivery: experience from a series of DBS babies. Front Neurol. 2015;6. https:\/\/doi.org\/10.3389\/fneur.2015.00191.","DOI":"10.3389\/fneur.2015.00191"},{"key":"1470_CR120","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3233\/JPD-240088","volume":"14","author":"K Smilowska","year":"2024","unstructured":"Smilowska K, Mehanna R, Fleisher JE, Alcalay RN, Kumar KR, Marras C, et al. Unmet need in early-onset Parkinson\u2019s disease: deep brain stimulation and pregnancy. J Parkinsons Dis. 2024;14:1277\u201382. https:\/\/doi.org\/10.3233\/JPD-240088.","journal-title":"J Parkinsons Dis"},{"key":"1470_CR121","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","volume":"42","author":"H Deng","year":"2018","unstructured":"Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev. 2018;42:72\u201385. https:\/\/doi.org\/10.1016\/j.arr.2017.12.007.","journal-title":"Ageing Res Rev"},{"key":"1470_CR122","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e318253d54b","volume":"78","author":"RN Alcalay","year":"2012","unstructured":"Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-X, Rosado L, Orbe Reilly M, et al. Cognitive performance of GBA mutation carriers with early-onset PD. Neurology. 2012;78:1434\u201340. https:\/\/doi.org\/10.1212\/WNL.0b013e318253d54b.","journal-title":"Neurology"},{"key":"1470_CR123","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ana.26302","volume":"91","author":"G Pal","year":"2022","unstructured":"Pal G, Mangone G, Hill EJ, Ouyang B, Liu Y, Lythe V, et al. Parkinson disease and subthalamic nucleus deep brain stimulation: cognitive effects in GBA mutation carriers. Ann Neurol. 2022;91:424\u201335. https:\/\/doi.org\/10.1002\/ana.26302.","journal-title":"Ann Neurol"},{"key":"1470_CR124","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332387","author":"M Avenali","year":"2023","unstructured":"Avenali M, Zangaglia R, Cuconato G, Palmieri I, Albanese A, Artusi CA, et al. Are patients with GBA\u2013Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort. J Neurol Neurosurg Psychiatry. 2023. https:\/\/doi.org\/10.1136\/jnnp-2023-332387. ;jnnp-2023-332387.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1470_CR125","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ana.26499","volume":"92","author":"WKW Fung","year":"2022","unstructured":"Fung WKW, Cohn M, Lang AE, Fasano A. Precision vs. personalized DBS for GBA-related Parkinson Disease. Ann Neurol. 2022;92:906\u20138. https:\/\/doi.org\/10.1002\/ana.26499.","journal-title":"Ann Neurol"},{"key":"1470_CR126","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/mdc3.13994","volume":"11","author":"E Asimakidou","year":"2024","unstructured":"Asimakidou E, Xiromerisiou G, Sidiropoulos C. Motor and non-motor outcomes of deep brain stimulation across the genetic panorama of parkinson\u2019s disease: a multi\u2010scale meta\u2010analysis. Mov Disord Clin Pract. 2024;11:465\u201377. https:\/\/doi.org\/10.1002\/mdc3.13994.","journal-title":"Mov Disord Clin Pract"},{"key":"1470_CR127","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40120-020-00220-5","volume":"10","author":"KLK Au","year":"2021","unstructured":"Au KLK, Wong JK, Tsuboi T, Eisinger RS, Moore K, Lemos Melo Lobo Jofili, Lopes J, et al. Globus pallidus internus (GPi) deep brain stimulation for parkinson\u2019s disease: expert review and commentary. Neurol Ther. 2021;10:7\u201330. https:\/\/doi.org\/10.1007\/s40120-020-00220-5.","journal-title":"Neurol Ther"},{"key":"1470_CR128","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","volume":"362","author":"KA Follett","year":"2010","unstructured":"Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al. Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson\u2019s Disease. N Engl J Med. 2010;362:2077\u201391. https:\/\/doi.org\/10.1056\/NEJMoa0907083.","journal-title":"N Engl J Med"},{"key":"1470_CR129","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1212\/WNL.0000000000002401","volume":"86","author":"VJJ Odekerken","year":"2016","unstructured":"Odekerken VJJ, Boel JA, Schmand BA, de Haan RJ, Figee M, van den Munckhof P, et al. GPi vs STN deep brain stimulation for Parkinson disease. Neurology. 2016;86:755\u201361. https:\/\/doi.org\/10.1212\/WNL.0000000000002401.","journal-title":"Neurology"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01470-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:46:45Z","timestamp":1766040405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01470-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01470-2","relation":{},"ISSN":["1534-6293"],"issn-type":[{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.H. received consulting fees from Lorentz Bio, travel support from Brain Computer Interface Conference. M.F. received research support from American Parkinson\u2019s Disease Association, National Institutes of Health (BIRCWH K12, NIA K76 Beeson), Michael J. Fox Foundation, Anschutz Acceleration Initiative. E.F. received research support from Biogen, Neuron 23 Inc, Bial R&D Investments. S.A. received research support from the University of Colorado, Michael J. Fox Foundation, Roche, Medtronic, Abbvie. A.J.B. received research support from the University of Colorado, NeuroNEXT Clinical Research Scholarship, Medtronic, BlueRock Therapeutics, PhotoPharmics, Beacon Biosignals; honoraria from Parkinson Association of the Rockies; travel support from Medtronic, Boston Scientific. J.S.F. received research support from the University of Colorado, Michael J. Fox Foundation, Mowry Fund; honoraria from Dystonia Medical Research Foundation; travel support from American Academy of Neurology, Dystonia Medical Research Foundation; is on the board for Jazz Pharmaceuticals and Colorado Neurological Society. E.B. received research support from the National Institutes of Health, Lewy Body Dementia Association, honoraria from Michael J. Fox Foundation, travel support from Organization for the Study of Sex Differences, Society for Equity Neuroscience, serves on committees for International Parkinson and Movement Disorders Society, Alzheimer\u2019s Association ISTAART, Michael J. Fox Foundation Data Community of Practice. A.T., M.K. declare they have no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3"}}